{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T18:41:12Z","timestamp":1770576072338,"version":"3.49.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.eururo.2012.11.024","type":"journal-article","created":{"date-parts":[[2012,11,16]],"date-time":"2012-11-16T16:45:30Z","timestamp":1353084330000},"page":"306-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mirabegron as a New Class of Oral Drug for Overactive Bladder Syndrome: Many Positive Perspectives, Some Concerns"],"prefix":"10.1016","volume":"63","author":[{"given":"Giacomo","family":"Novara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Nicolas","family":"Cornu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2012.11.024_bib0005","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.11.024_bib0010","series-title":"Incontinence: 4th International Consultation on Incontinence","first-page":"631","article-title":"Pharmacological treatment of urinary incontinence","author":"Andersson","year":"2009"},{"key":"10.1016\/j.eururo.2012.11.024_bib0055","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","article-title":"Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses","volume":"62","author":"Buser","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.11.024_bib0020","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","article-title":"Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis","volume":"62","author":"Madhuvrata","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.11.024_bib0025","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","article-title":"Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA)","volume":"60","author":"Mangera","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.11.024_bib0065","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder: results from a randomized European\u2013Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.11.024_bib0070","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized, double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b23 adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.11.024_bib0060","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.eururo.2012.08.056","article-title":"Effects of mirabegron, a novel \u03b23-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin","volume":"62","author":"Aizawa","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.11.024_bib0045","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2012.05.053","article-title":"A multicenter, double-blind, randomized, placebo-controlled trial of the \u03b23-adrenoceptor agonist solabegron for overactive bladder","volume":"62","author":"Ohlstein","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.11.024_bib0050","doi-asserted-by":"crossref","unstructured":"Nitti V, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. In press. http:\/\/dx.doi.org\/10.1016\/j.juro.2012.10.017.","DOI":"10.1016\/j.juro.2012.10.017"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812013553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812013553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:02:47Z","timestamp":1759582967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283812013553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0302283812013553"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2012.11.024","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirabegron as a New Class of Oral Drug for Overactive Bladder Syndrome: Many Positive Perspectives, Some Concerns","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2012.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2012.10.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2012.10.048","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}